COVID-19 and Health Outcomes in People with Multiple Sclerosis: A Population-Based Study in Italy

被引:0
作者
Gnavi, Roberto [1 ]
Eboli, Ilenia [1 ]
Alboini, Paolo Emilio [2 ]
D'Alfonso, Sandra [3 ,4 ]
Picariello, Roberta [1 ]
Costa, Giuseppe [1 ,5 ]
Leone, Maurizio [2 ]
机构
[1] ASL TO3 Reg Piemonte, Epidemiol Unit, I-10095 Grugliasco, Italy
[2] Fdn IRCCS Casa Sollievo della Sofferenza, Neurol Unit, I-71013 San Giovanni Rotondo, Italy
[3] Univ Piemonte Orientale, Dept Hlth Sci, I-28100 Novara, Italy
[4] Univ Piemonte Orientale, CAAD, I-28100 Novara, Italy
[5] Univ Turin, Dept Biol & Clin Sci, I-10128 Turin, Italy
来源
LIFE-BASEL | 2023年 / 13卷 / 05期
关键词
multiple sclerosis; COVID-19; outcome assessment; health care;
D O I
10.3390/life13051089
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
People with multiple sclerosis (PWMS) are at high risk of being affected by the disruption of health services that occurred during the COVID-19 pandemic months. The aim of this study was to evaluate the effect of the pandemic on the health outcomes of PWMS. PWMS and MS-free residing in Piedmont (north-west of Italy) were identified from electronic health records and linked with the regional COVID-19 database, the hospital-discharge database, and the population registry. Both cohorts (9333 PWMS and 4,145,856 MS-free persons) were followed-up for access to swab testing, hospitalisation, access to the Intensive Care Unit (ICU), and death from 22 February 2020 to 30 April 2021. The relationship between the outcomes and MS was evaluated using a logistic model, which was adjusted for potential confounders. The rate of swab testing was higher in PWMS, but the positivity to infection was similar to that of MS-free subjects. PWMS had a higher risk of hospitalisation (OR = 1.74; 95% IC, 1.41-2.14), admission to ICU (OR = 1.79; 95% IC, 1.17-2.72), and a slight, albeit not statistically significant, increase in mortality (OR = 1.28; 95% IC, 0.79-2.06). Compared to the general population PWMS with COVID-19 had an increased risk of hospitalization and admission to the ICU; the mortality rate did not differ.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] People With Functional Disability and Access to Health Care During the COVID-19 Pandemic A US Population-based Study
    Xie, Zhigang
    Hong, Young-Rock
    Tanner, Rebecca
    Marlow, Nicole M.
    MEDICAL CARE, 2023, 61 (02) : 58 - 66
  • [22] COVID-19 outcomes in persons with multiple sclerosis treated with rituximab
    Iyer, Rajesh B.
    Raghavendra, S.
    Nooraine, Javeria M.
    Jaychandran, R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [23] Mental Health and Substance Use Associated with Hospitalization among People with COVID-19: A Population-Based Cohort Study
    Garcia, Hector Alexander Velasquez
    Wilton, James
    Smolina, Kate
    Chong, Mei
    Rasali, Drona
    Otterstatter, Michael
    Rose, Caren
    Prystajecky, Natalie
    David, Samara
    Galanis, Eleni
    McKee, Geoffrey
    Krajden, Mel
    Janjua, Naveed Zafar
    VIRUSES-BASEL, 2021, 13 (11):
  • [24] Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients
    Zanetta, Chiara
    Rocca, Maria A.
    Filippi, Massimo
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (05) : 495 - 512
  • [25] Multiple sclerosis and COVID-19
    Mares, Jan
    Hartung, Hans-Peter
    BIOMEDICAL PAPERS-OLOMOUC, 2020, 164 (03): : 217 - 225
  • [26] Clinical characteristics and outcomes of people with severe mental disorders hospitalized due to COVID-19: A nationwide population-based study
    Lopez-Cuadrado, Teresa
    Szmulewicz, Alejandro
    Ongur, Dost
    Martinez-Ales, Gonzalo
    GENERAL HOSPITAL PSYCHIATRY, 2023, 84 : 234 - 240
  • [27] Physical activity in people with multiple sclerosis and the impact of the COVID-19 pandemic
    Novotna, K.
    Grosserova, B.
    Kovari, M.
    Geierova, L.
    Struskova, E.
    Havrdova, E. Kubala
    Vetrovska, R.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2024, 87 (04) : 248 - 254
  • [28] Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
    Habek, Mario
    Piskac, Dominik
    Gabelic, Tereza
    Barun, Barbara
    Adamec, Ivan
    Skoric, Magdalena Krbot
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 62
  • [29] COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy
    Crisafulli, Salvatore
    Ientile, Valentina
    L'Abbate, Luca
    Fontana, Andrea
    Linguiti, Claudio
    Manna, Sonia
    Mercaldo, Mariangela
    Pagliaro, Claudia
    Vezzaro, Michele
    Santaca, Katia
    Lora, Riccardo
    Moretti, Ugo
    Reno, Chiara
    Fantini, Maria Pia
    Corrao, Salvatore
    Barbato, Donato
    Tari, Michele
    Trifiro, Gianluca
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (01)
  • [30] Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study
    Jang, Han Na
    Moon, Sun Joon
    Jung, Jin Hyung
    Han, Kyung-Do
    Rhee, Eun-Jung
    Lee, Won-Young
    ENDOCRINOLOGY AND METABOLISM, 2024, 39 (03) : 479 - 488